Key facts
- Japanese traditional drugmakers are developing domestic supply chains to reduce reliance on Chinese imports for raw materials.
- Tsumura & Co. is one of the companies pursuing this strategy.
Japanese traditional medicine companies, including Tsumura & Co., are actively developing domestic supply chains to lessen their reliance on Chinese imports for essential raw materials. This strategic shift aims to bolster supply chain resilience and reduce vulnerability to geopolitical or logistical disruptions. The company is working to procure ingredients from domestic farmers as the market for traditional remedies grows.